Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Galapagos and LEO Pharma Collaborate on Antibacterial Research

  • BioFocus, Galapagos' service division, will use a subset of its natural compound collection for high-throughput screening, hit verification, and profiling of selected compounds for LEO Pharma's antibacterial research program. This collaboration marks Galapagos' first for its natural compound collection.

    Galapagos stands to receive up to EUR 400,000 in project fees and up to EUR 3 million in milestone payments. The company may also receive royalties on sales of commercial products resulting from the collaboration. 

    BioFocus says its natural compound collections are based on bacterial and fungal sources, offering characteristics differentiating these from synthetic chemistry collections, including high chemical and functional diversity, potent pharmacological activities over a broad range of biological targets, and desirable physicochemical properties.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »